HRP20090573T1 - Postupak za otapanje, dispergiranje i stabiliziranje supstanci, prema postupku proizvedeni proizvodi, kao i njihova uporaba - Google Patents

Postupak za otapanje, dispergiranje i stabiliziranje supstanci, prema postupku proizvedeni proizvodi, kao i njihova uporaba Download PDF

Info

Publication number
HRP20090573T1
HRP20090573T1 HR20090573T HRP20090573T HRP20090573T1 HR P20090573 T1 HRP20090573 T1 HR P20090573T1 HR 20090573 T HR20090573 T HR 20090573T HR P20090573 T HRP20090573 T HR P20090573T HR P20090573 T1 HRP20090573 T1 HR P20090573T1
Authority
HR
Croatia
Prior art keywords
melt
poloxamer
water
active substance
plant
Prior art date
Application number
HR20090573T
Other languages
English (en)
Inventor
Strobel Hanspeter
Original Assignee
Laboswiss Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboswiss Ag filed Critical Laboswiss Ag
Publication of HRP20090573T1 publication Critical patent/HRP20090573T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988—Honey; Royal jelly, Propolis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Abstract

Postupak za otapanje, dispergiranje i stabiliziranje supstanci, naznačen time, da se u kombiniranu talinu stali s jedne strane jedan poloksamer i s druge strane jedna smola i/ili tokoferol, a supstanca koju treba obraditi se bez dodatka vode dispergira ili otopi u talini, tako da se zatim u ovoj talini u svako doba dodatkom proizvoljne količine vode mogu proizvesti stabilni miceliji, koji sadrže i/ili vežu supstance. Patent sadrži još 30 patentnih zahtjeva.

Claims (31)

1. Postupak za otapanje, dispergiranje i stabiliziranje supstanci, naznačen time, da se u kombiniranu talinu stali s jedne strane jedan poloksamer i s druge strane jedna smola i/ili tokoferol, a supstanca koju treba obraditi se bez dodatka vode dispergira ili otopi u talini, tako da se zatim u ovoj talini u svako doba dodatkom proizvoljne količine vode mogu proizvesti stabilni miceliji, koji sadrže i/ili vežu supstance.
2. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema patentnom zahtjevu 1, naznačen time, da se proizvedena talina prekriva vodom iste temperature radi sprječavanja otvrdnjavanja i da se na taj način stvoreni gel homogenizira.
3. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema patentnom zahtjevu 1, naznačen time, da se jedan poloksamer, t.j. primjerice Poloxamer 188 i/ili Poloxamer 407 i/ili jedan od njihovih supstituta i/ili derivata, kombiniran s jednom smolom i /ili jednim tokoferolom zajedno rastale, a supstanca koju treba obraditi se dispergira unutar ove taline, kod čega se nakon unošenja u talinu supstance koju treba obraditi, talina prekriva vodom radi sprječavanja otvrdnjavanja i talina se homogenizira.
4. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema jednom od prethodnih patentnih zahtjeva, naznačen time, da se jedan poloksamer kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale pri temperaturi taljenja, temperatura taline se snizi dodatkom otapala, supstanca koju treba otapati se dispergira u talini, talina se radi sprječavanja otvrdnjavanja prekrije vodom iste temperature i zatim se talina homogenizira, uslijed čega nastaje transparentni gel kao produkt otapanja.
5. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema jednom od prethodnih patentnih zahtjeva, naznačen time, da se jedan poloksamer kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale pri temperaturi od cca. 40-60oC, temperatura taline se snizi dodavanjem jednog ili više otapala izabranih između glicerina, propilen-glikola, polietilen-glikola 400, etanola, Macrogola 400, izopropanola, zatim se supstanca koju treba otopiti, a koja može biti termolabilna, osobito inzulin, dispergira u talini, talina se radi sprječavanja otvrdnjavanja prekrije vodom iste temperature i zatim se talina homogenizira, uslijed čega nastane transparentni gel kao produkt otapanja.
6. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema patentnom zahtjevu 1, naznačen time, da se barem jedan poloksamer kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale i unutar ove taline se dispergira ili otopi djelatna tvar za biljke koju treba obraditi, kod čega se ista potom tako dugo hladi dok ne postane krta, nakon toga se melje u mlinu i zatim se s vodom u emulgatoru valja u mokrom ili se u mokrom zdrobi u mlinu čekičaru, dok se kristali taline ne smanje na promjer manji od 5 mikrometara, čime se proizvede suspenzija koja se može dodati biljci ili rahloj zemlji za biljke radi apsorpcije.
7. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema patentnom zahtjevu 6, naznačen time, da se jedan poloksamer, to jest primjerice Poloxamer 188 i/ili Poloxamer 407 i/ili jedan od njihovih supstituta i/ili derivata kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale, a djelatna tvar za biljke koju treba obraditi se dispergira unutar ove taline, kod čega se nakon unošenja u talinu djelatne tvari za biljke koju treba obraditi, ona zatim ohladi, dok ne postane krtom, samelje i nakon toga smanji na promjer kristala taline manji od 5 mikrometara, koji se zatim otope u vodi ili dispergiraju, tako da se otopina može dodati rahloj zemlji za biljke radi apsorpcije putem korijena biljke ili se može izravno prskati na nadzemni dio biljke.
8. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema jednom od patentnih zahtjeva 6 do 7, naznačen time, da se jedan poloksamer kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale pri temperaturi od cca. 40-60oC, temperatura taline se snizi dodatkom otapala, djelatna tvar za biljke koja se treba otapati se dispergira u talini, talina se potom ohladi, dok ne postane krtom, grubo ju se samelje u mlinu za sječenje i zatim se s vodom u mlinu čekičaru ili mlinu za emulgiranje fino samelje u mokrom, dok se kristali taline ne smanje na promjer manji od 5 mikrometara, kristali taline se zatim dalje otapaju u vodi ili dispergiraju, tako da se otopina može dodati rahloj zemlji za biljke radi apsorpcije putem njezinog korijena ili se može izravno prskati na nadzemni dio biljke.
9. Postupak za otapanje, dispergiranje i stabiliziranje supstanci prema jednom od patentnih zahtjeva 6 do 8, naznačen time, da se jedan poloksamer kombiniran s jednom smolom i/ili jednim tokoferolom zajedno rastale pri temperaturi od cca. 40-60oC, temperatura taline snizi se dodatkom jednog ili više otapala izabranih između glicerina, propilen-glikola, polietilen-glikola 400, etanola, Macrogola 400, izopropanola, zatim se djelatna tvar za biljke koja može biti termolabilna, a koju treba otopiti, dispergira u talini, talina se zatim ohladi dok ne postane krtom i grubo samelje u mlinu za sječenje, a potom se s vodom u mlinu čekičaru ili mlinu za emulgiranje fino samelje u mokrom, dok se kristali taline ne smanje na promjer manji od 5 mikrometara, kristali taline se zatim dalje otapaju u vodi ili dispergiraju, tako da se otopina može dodati rahlom tlu za biljke radi apsorpcije putem korijena biljke ili se može prskati izravno na nadzemni dio biljke.
10. Stabilizirani proizvod, koji se sastoji iz taline ili transparentnog gela koji se može dobiti prema postupku prema patentnim zahtjevima 1 do 8, naznačen time, da je na bazi od barem jednog poloksamera u kombinaciji s prirodnom ili umjetno pripremljenom smolom i/ili jednim tokoferolom, kao i iz jedne u tome otopljene i stabilizirane djelatne tvari, s konzistencijom između krute i polukrute, to znači poput aspika do tekuće.
11. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da se sastoji iz transparentnog gela, polukrute, to znači poput aspika, do tekuće konzistencije, na bazi barem jednog poloksamera, to jest Poloxamera 188 i/ili Poloxamera 407 i/ili jednog od njihovih supstituta i/ili derivata u kombinaciji s jednom smolom i/ili jednim tokoferolom, jednog otapala izabranog između glicerina, propilen-glikola, polietilen-glikola 400, etanola, Macrogola 400, izopropanola, kao i iz jedne, u tome otopljene, dispergirane i stabilizirane lipofilne ili hidrofilne djelatne tvari.
12. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da sadrži vitamine C, E i ACC, i u obliku je šampona preostalog sastava: Voda 74,11% Natrijev lauril eter sulfat 11,67% Cocamidopropil Betain 2,00% Cocamide DEA 1,70% Dinatrijev lauril eter sulfosukcinat 1,32% Miomiris 1,00% Poloxamer 407 1,40% Poloxamer 188 0,60% Askorbinska kiselina 1,00% Acetil cistein 1,00% Alfa-tokoferoli 0,50% Natrijev lauril sulfat 0,80% Fenoksietanol 0,50% ̧ Imidazolidinil urea 0,20% PEG-120 metil glukoza dioleat 0,10% Tetranatrij EDTA 0,10%
13. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da je u obliku gela koji sadrži koenzim Q10, vitamin C i vitamin E, sa sastavom: Voda 71,43% Poloxamer 188 8,93% Poloxameri 407 8,93% Alfa-tokoferol 5,00% Koenzim Q10 2,14% Askorbinska kiselina 3,57%
14. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da je u obliku gela, koji sadrži propolis, sa sljedećim sastavom: Voda 70% Poloxamer 188 18% Propolis 13%
15. Stabilizirani proizvod u krutom ili polukrutom obliku prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da sadrži koncentrate djelatne tvari, čija talina ili gel djeluju kao vodenom parom opterećena i time hidrofilna i/ili u vodi topiva krutina velike površine, komprimirana kao želatinske kapsule, kao dozirne vrećice s prahom ili kao tablete i šumeće tablete.
16. Stabilizirani proizvod u krutom ili polukrutom obliku prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 2 do 5, naznačen time, da sadrži koncentrate djelatne tvari, čija talina ili gel djeluje kao vodenom parom opterećena i time hidrofilna i/ili u vodi topiva krutina velike površine, komprimirana kao želatinske kapsule, tablete ili šumeće tablete, kod čega se hidrofilne ili u vodi topive krutine velike površine ili one s površinom koja je povećana sušenjem pomoću raspršivanja i/ili smrzavanja (sa specifičnom površinom >0,01 m2/g po BET-metodi) sastoje iz jedne ili više od sljedećih supstanci: - Eksudati, kao na pr. gumiarabika, tragant, karaja guma, gati guma, - Brašna za ugušćivanje, kao na pr. guar guma, brašno od zrna rogača, brašno od zrna peruanskog rogača, tamarind guma, - Nosive supstance, kao na pr. ariševa guma, pektin, agar, alginat, karagin, furcelaran, - Biosintetički hidrokoloidi, kao na pr. ksantan, - Modificirani hidrokoloidi, kao na pr. propilenglikolalginat, amidirani pektin, - Derivati celuloze, kao na pr. metilceluloza, metiletilceluloza, metilhidroksietilceluloza, metilhidroksipropilceluloza, hidroksipropilceluloza, natrij-karboksimetilceluloza, - Silicijev oksid, kao na pr. Aerosil, - Proteini, kao na pr. želatina, prah od obranog mlijeka, - Šećeri, kao laktoza, manit, ksilit, sorbit, dekstran.
17. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 5, naznačen time, da sadrži jednu ili više od sljedećih lipofilnih ili hidrofilnih supstanci, koje su prikladne za nadopune hrani, za kozmetičke i dermatološke proizvode, to jest koenzim Q10, vitamin C, Vitamin E, betakarotin, vitamin A, vitamin D3, lutein, likopen, folnu kiselinu, vitamin B12, Ω-3- i Ω-6-masne kiseline.
18. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 5, naznačen time, da sadrži jednu ili više supstanci kao što je inzulin, (antidiabetici), ciklosporin, biljne ekstrakte iz mliječnog čička, božje krunice i repuha i njihove derivate (primjerice silimarin, krizin i t.d.).
19. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 5, naznačen time, da sadrži polifenilne spojeve sa sadržajem djelatne tvari od 2-5% u vodenoj sredini.
20. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 5, naznačen time, da sadrži supstance poput smole protiv infekcija ili za konzerviranje supstanci.
21. Stabilizirani proizvod prema patentnom zahtjevu 10, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 5, naznačen time, da sadrži supstance za zbrinjavanje rana na bazi propolisa, selenovog dioksida, katrana i/ili mineralnih ulja.
22. Stabilizirani proizvod u obliku supstrata djelatne tvari za rast biljaka, koji se može dobiti postupkom prema patentnim zahtjevima 1 do 8, naznačen time, da se sastoji iz suspenzije topive u vodi ili otopine, koja sadrži djelatnu tvar ili čestice taline djelatne tvari u transparentnoj smjesi na bazi od barem jednog poloksamera, jedne smole i/ili jednog tokoferola, kod čega kristali taline imaju dimenziju maksimalno 5 mikrometara.
23. Stabilizirani proizvod u obliku supstrata djelatne tvari za rast biljaka prema patentnom zahtjevu 22, naznačen time, da se sastoji iz kristala taline na bazi od barem jednog poloksamera, jedne smole i/ili jednog tokoferola i jedne, u tome otopljene i stabilizirane djelatne tvari za biljke, kod čega su kristali taline 5 mikrometara ili manji.
24. Stabilizirani proizvod u obliku supstrata djelatne tvari za rast biljaka prema jednom od patentnih zahtjeva 22 ili 23, naznačen time, da se sastoji iz kristala taline na bazi od barem Poloxamera 188 i/ili Poloxamera 407 i/ili jednog od njihovih supstituta i/ili derivata s jednom smolom i/ili jednim tokoferolom, jednog otapala izabranog između glicerina, propilen-glikola, polietilen-glikola 400, etanola, Macrogola 400, izopropanola, kao i iz u tome otopljene, dispergirane i stabilizirane lipofilne ili hidrofilne djelatne tvari za biljke.
25. Stabilizirani proizvod u obliku supstrata djelatne tvari za rast biljaka prema jednom od patentnih zahtjeva 22 do 24, naznačen time, da je otopljen u hidrofilnim ili u vodi topivim krutinama velike površine ili s površinom koja je povećana sušenjem pomoću raspršivanja i/ili smrzavanja (specifična površina >0,01 m2/g po BET-metodi), kod čega su ove supstance jedna ili više iz sljedećeg izbora: - Eksudati, kao na pr. gumiarabika, tragant, karaja guma, gati guma, - Brašna za ugušćivanje, kao na pr. guar guma, brašno od zrna rogača, brašno od zrna peruanskog rogača, tamarind guma, - Nosive supstance, kao na pr. ariševa guma, pektin, agar, alginat, karagin, furcelaran, - Biosintetički hidrokoloidi, kao na pr. ksantan, - Modificirani hidrokoloidi, kao na pr. propilenglikolalginat, amidirani pektin, - Derivati celuloze, kao na pr. metilceluloza, metiletilceluloza, metilhidroksietilceluloza, metilhidroksipropilceluloza, hidroksipropilceluloza, natrij-karboksimetilceluloza, - Silicijev oksid, kao na pr. Aerosil, - Proteini, kao na pr. želatina, prah od obranog mlijeka, - Šećeri, kao laktoza, manit, ksilit, sorbit, dekstran.
26. Uporaba proizvoda prema patentnom zahtjevu 10 ili 11, naznačena time, da je za otapanje masti, proteina, smola i supstanci poput smole svih vrsta, radi skidanja masti, proteina, smola i supstanci poput smole svih vrsta s površina.
27. Uporaba proizvoda prema patentnom zahtjevu 10 ili 11, naznačena time, da je za održavanje i čišćenje predmeta.
28. Uporaba proizvoda prema patentnom zahtjevu 10 ili 11, naznačena time, da ga se koristi kao mazivo.
29. Uporaba proizvoda prema patentnom zahtjevu 10 ili 11, naznačena time, da je za maskiranje supstance radi suzbijanja njezinog mirisa i/ili okusa.
30. Uporaba stabiliziranog proizvoda u obliku supstrata djelatne tvari, proizvedenog u skladu s postupkom prema jednom od patentnih zahtjeva 22 do 25, u obliku suspenzije ili otopine, koja sadrži djelatnu tvar ili čestice taline djelatne tvari u transparentnoj smjesi na bazi barem jednog poloksamera, jedne smole i/ili jednog tokoferola, kod čega kristali taline imaju dimenziju od maksimalno 5 mikrometara, naznačena time, da jest za utjecaj na rast biljke, time što se suspenzija ili otopina u vodi u otopljenom ili suspendiranom stanju dodaje rahloj zemlji biljke radi apsorpcije preko korijena, ili se ona izravno prska na nadzemni dio biljke.
31. Uporaba stabiliziranog proizvoda u obliku supstrata djelatne tvari prema jednom od patentnih zahtjeva 22 do 25, naznačena time, da je za utjecaj na rast biljke, time što se on otopljen u vodi dodaje rahloj zemlji biljke radi apsorpcije preko korijena, ili se izravno prska na nadzemni dio biljke.
HR20090573T 2006-03-10 2009-10-28 Postupak za otapanje, dispergiranje i stabiliziranje supstanci, prema postupku proizvedeni proizvodi, kao i njihova uporaba HRP20090573T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3772006 2006-03-10
PCT/CH2007/000131 WO2007104173A2 (de) 2006-03-10 2007-03-09 Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben

Publications (1)

Publication Number Publication Date
HRP20090573T1 true HRP20090573T1 (hr) 2009-11-30

Family

ID=38137765

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090573T HRP20090573T1 (hr) 2006-03-10 2009-10-28 Postupak za otapanje, dispergiranje i stabiliziranje supstanci, prema postupku proizvedeni proizvodi, kao i njihova uporaba

Country Status (17)

Country Link
US (2) US8703195B2 (hr)
EP (1) EP1993515B1 (hr)
JP (2) JP5678359B2 (hr)
KR (1) KR101433962B1 (hr)
CN (1) CN101400337A (hr)
AT (1) ATE437627T1 (hr)
AU (1) AU2007224940B2 (hr)
BR (1) BRPI0708773B1 (hr)
CA (1) CA2643389C (hr)
DE (1) DE502007001190D1 (hr)
DK (1) DK1993515T3 (hr)
EA (1) EA026670B1 (hr)
ES (1) ES2330898T3 (hr)
HR (1) HRP20090573T1 (hr)
PL (1) PL1993515T3 (hr)
PT (1) PT1993515E (hr)
WO (1) WO2007104173A2 (hr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008297899A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
KR20100056523A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｇｒｆ-1 (1-29) 및 코르티코트로핀-방출 인자의 용도
JP2010539049A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト サイモシンβ４の単独、またはセクロピンＡとの組合せでの、治療剤としてのペプチドの使用
AU2008303942A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of BFGF 1-24 and optionally (ARG 8) vasopressin to treat eg S. pneumoniae infection
WO2009043527A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Therapeutic use of human growth hormone 1-43
CA2698852A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2699065A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008303849A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Therapeutic use of peptide YGLF and combination with KVLPVPQ
AU2008297905A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a laminin peptide as a therapeutic agent
KR20100056516A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 가스트린－１ 및 ｇ－ｐｅｎ－ｇｒｇｄｓｐｃａ의 치료적 용도
EP2197462A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent
KR20100061486A (ko) 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
KR20100056518A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
WO2009046827A2 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20180056816A (ko) 2009-05-11 2018-05-29 베르그 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
EP2359702B1 (en) 2010-01-22 2014-06-04 Symrise AG Solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides
EP2544663B1 (en) * 2010-03-12 2018-01-03 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
ATE547484T2 (de) 2010-05-28 2012-03-15 Omya Development Ag Verfahren zur herstellung von hochfesten suspensionen aus mineralmaterialien
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
MY183615A (en) 2011-06-17 2021-03-03 Berg Llc Inhalable pharmaceutical compositions
JP5869856B2 (ja) * 2011-11-30 2016-02-24 キユーピー株式会社 容器入り大根おろし含有液状調味料
BRPI1106762A2 (pt) * 2011-12-22 2013-11-05 Bioactive Biomateriais Ltda Composição polimérica contendo bioativos naturais aplicáveis em formulações farmacêuticas e cosméticas
KR101451401B1 (ko) * 2012-12-14 2014-10-22 주식회사 휴메딕스 비타민 c와 비타민 e의 컨쥬게이트 및 그를 포함하는 항산화제
JP6122646B2 (ja) * 2013-01-23 2017-04-26 昭和電工株式会社 皮膚外用剤
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
BR112015027112A2 (pt) * 2013-05-06 2017-07-25 Basf Se uso de uma mistura, e, formulação de ingrediente ativo aquoso
JP6232807B2 (ja) * 2013-07-30 2017-11-22 ユーハ味覚糖株式会社 グミキャンディ
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3216443A1 (en) 2016-03-10 2017-09-13 Athenion AG Beverage preparation capsule for delivery of a solubilisate
EP3388054A1 (en) 2017-04-12 2018-10-17 Athenion AG Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN108271814A (zh) * 2018-01-21 2018-07-13 王小凤 一种糖尿病患者可食用的苹果的培育剂及其制备方法
CN108210360B (zh) * 2018-02-06 2021-02-12 德之馨（上海）有限公司 一种水溶性美白配方及其制备方法和用途
ES2939010T3 (es) * 2018-10-24 2023-04-18 Syngenta Participations Ag Nueva composición de concentrado soluble de abamectina (SL)
WO2020250242A1 (en) * 2019-06-10 2020-12-17 Godrej Agrovet Limited Bud break formulation
JP2021104985A (ja) * 2019-12-27 2021-07-26 ポーラ化成工業株式会社 透明な可溶化組成物
EP3909564A1 (de) 2020-05-12 2021-11-17 Metabolic Tuning AG Feste lösung aus gummi arabicum und wenigstens einem fettlöslichen wirkstoff
KR102365402B1 (ko) * 2021-05-31 2022-02-18 김상태 사포닌을 함유한 깻잎 및 이의 생산방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953496A (en) * 1958-12-02 1960-09-20 Upjohn Co Vitamin emulsion
CA1088427A (en) * 1975-12-22 1980-10-28 Andrew W. Finkstein Imidazoline-containing hair shampoo compositions
JPS5660565A (en) * 1979-10-22 1981-05-25 Dainichiseika Color Chem Composition for deodorizing aromatic
US4383987A (en) * 1981-06-26 1983-05-17 Colgate/Palmolive Company Foaming dentifrice containing nonionic surface active agent
GB2181737A (en) * 1985-08-29 1987-04-29 Avent Medical Ltd Liquid shampoo composition
US4810503A (en) * 1987-03-31 1989-03-07 Basf Corporation Polymers which form gels at low concentrations in water
ZA95519B (en) * 1994-02-07 1995-09-28 Isk Biotech Corp Pesticidal micronutrient com psitions containing zinc oxide
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6193954B1 (en) * 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6027716A (en) * 1997-04-02 2000-02-22 Farmo-Nat Ltd. Synergistic herbal extracts
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
AUPP915099A0 (en) * 1999-03-12 1999-04-15 Monk, Michael Mendel Improved composition for oral administration
BR0010794A (pt) * 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsão-veìculo para drogas com fraca solubilidade
JP2003509350A (ja) * 1999-09-11 2003-03-11 ザ、プロクター、エンド、ギャンブル、カンパニー 注加可能な液体賦形剤
FR2806909B3 (fr) * 2000-03-29 2002-03-22 Giorgio Panin Composition detergente pour l'hygiene personnelle, a haute teneur en vitamine e ou en derives de cette derniere
DE10343872A1 (de) * 2003-09-23 2005-04-21 Bayer Cropscience Ag Suspensionskonzentrate
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol

Also Published As

Publication number Publication date
EA026670B1 (ru) 2017-05-31
US8703195B2 (en) 2014-04-22
EP1993515A2 (de) 2008-11-26
CA2643389C (en) 2014-12-02
JP2009531305A (ja) 2009-09-03
US20140193513A1 (en) 2014-07-10
DK1993515T3 (da) 2009-12-07
AU2007224940B2 (en) 2013-08-29
US20090280987A1 (en) 2009-11-12
ATE437627T1 (de) 2009-08-15
BRPI0708773A2 (pt) 2011-06-14
JP2015028028A (ja) 2015-02-12
KR20080108262A (ko) 2008-12-12
KR101433962B1 (ko) 2014-08-25
WO2007104173A3 (de) 2007-11-22
CN101400337A (zh) 2009-04-01
PT1993515E (pt) 2009-11-05
JP5678359B2 (ja) 2015-03-04
PL1993515T3 (pl) 2010-01-29
AU2007224940A1 (en) 2007-09-20
US9114167B2 (en) 2015-08-25
EP1993515B1 (de) 2009-07-29
WO2007104173B1 (de) 2008-01-10
WO2007104173A2 (de) 2007-09-20
CA2643389A1 (en) 2007-09-20
DE502007001190D1 (de) 2009-09-10
ES2330898T3 (es) 2009-12-16
EA200801850A1 (ru) 2009-06-30
BRPI0708773B1 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
HRP20090573T1 (hr) Postupak za otapanje, dispergiranje i stabiliziranje supstanci, prema postupku proizvedeni proizvodi, kao i njihova uporaba
Thakur et al. Novel approaches for stability improvement in natural medicines
ES2863048T3 (es) Formulación de vitamina liposoluble
Liu et al. Enhanced skin permeation of glabridin using eutectic mixture-based nanoemulsion
CN107410295A (zh) 一种粒径小于100纳米的嘧菌酯水悬浮剂及其制备方法
Xia et al. In vitro evaluation of α-lipoic acid-loaded lipid nanocapsules for topical delivery
Mostafa et al. Transdermal fennel essential oil nanoemulsions with promising hepatic dysfunction healing effect: in vitro and in vivo study
US20150282509A1 (en) Food composition and soft capsule comprising same
CN104069266B (zh) 一种兽用植物精油组合物
Gurav et al. Solubility enhancement of satranidazole using self-emulsified drug delivery systems
KR101868481B1 (ko) 눈꽃모양 입자를 형성하는 보습 크림의 화장료 조성물과 이의 제조방법
WO2015064681A1 (ja) 外用組成物
KR101934828B1 (ko) 해수와, 본래 해수와 섞이지 않는 적어도 하나의 화합물을 함유하는 수용성 이온 용액
Chasquibol et al. Co-Microencapsulation of Sacha Inchi (Plukenetia huayllabambana) Oil with Natural Antioxidants Extracts
US20220287929A1 (en) Skin care product and method for its production
JP2016088912A (ja) Ｗ／ｏ／ｗ型エマルション
KR102272302B1 (ko) 곤드레 추출물을 함유하는 리포좀 조성물
CN113440453A (zh) 一种复合美白活性物纳米粒及其制备方法及应用
JP2008013461A (ja) 抗酸化組成物
US20220211787A1 (en) Encapsulated cannabinoid comestible noble metal compositions and products, methods of preparing same
Suksaeree et al. Formulation and characterization of topical anti-acne spot gel containing herbal extracts
Chookiat et al. Nanoemulsions Containing Mucuna pruriens (L.) DC. Seed Extract for Cosmetic Applications
CN109248144A (zh) 一种透明的脂质乳剂
CN113318036A (zh) 艾纳植物提取水的新应用
JP2017048129A (ja) ソフトカプセル剤およびその製造方法